AMENDMENTS TO THE CLAIMS

This listing of the claims below replaces all prior versions and listing of claims in this application.

Claims 1-8. (Cancelled)

Claim 9. (Currently Amended) A therapeutic composition comprising <u>human</u> interferon-γ as an active ingredient and a pharmaceutically acceptable carrier, said <u>human</u> interferon-γ being present in an amount effective to treat <u>bullous</u> pemphigoid, <u>wherein</u> said amount effective to treat <u>bullous</u> pemphigoid is 2,000,000-4,000,000 JRU.

Claims 10-11. (Cancelled)

Claim 12. (New) The composition of claim 9, wherein said an amount effective to treat bullous pemphigoid is 2,000,000 JRU.

Claim 13. (New) The composition of claim 9, further comprising an antihistaminic, an antiallergic, a corticosteroid, or any combination thereof.

Claim 14. (New) A method for treating bullous pemphigoid comprising administering to a patient human interferon-γ in a daily dose of 2,000,000-4,000,000 JRU.

Claim 15. (New) The method according to claim 14, wherein said daily dose is 2,000,000 JRU.

Claim 16. (New) The method according to claim 14, comprising administering said human interferon-γ intravenously.

Claim 17. (New) The method according to claim 14, comprising administering human interferon-γ in combination with an antihistaminic, an antiallergic, a corticosteroid, or any combination thereof.